Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neuroepithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Neuroepithelial, Perineurial, and Schwann Cell Neoplasm
Neuroepithelial Neoplasm

Cancer Family

Neuroepithelial Neoplasm

CI-CAN-00000287Explore in graph →

Non-malignant811 active trials6 approved drugs154 evidence items

NCIt: C3787
OncoTree: PRNET
UMLS CUI: C0206715
MeSH: D018302

Overview
Statistics
Survival
Genomics26
Variants & evidence154
Drugs34
Trials2934
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (109)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 26–50 of 109 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis.
· Acta Neuropathol Commun · 2019 · PMID 30876455 · validated civic_curation pubmed
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era.
· PLoS One · 2012 · PMID 22479427 · validated civic_curation pubmed
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
· Neurology · 2009 · PMID 19933982 · validated civic_curation pubmed
The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
· Acta Neuropathol · 2010 · PMID 20127344 · validated civic_curation pubmed
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
· Cancer Res · 2003 · PMID 14583498 · validated civic_curation pubmed
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
· Neuro Oncol · 2015 · PMID 25910840 · validated civic_curation pubmed
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
· Neuro Oncol · 2015 · PMID 25586468 · validated

Showing 26–50 of 109 publications

← Previous
1
2
3
4
5
Next →

civic_curation

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

· Acta Neuropathol · 2013 · PMID 23904111 · validated civic_curation pubmed

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

· J Clin Oncol · 2007 · PMID 17442989 · validated civic_curation pubmed

O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.

· PLoS One · 2011 · PMID 21365007 · validated civic_curation pubmed

O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.

· Brain Tumor Pathol · 2011 · PMID 21331613 · validated civic_curation pubmed

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.

· Nat Genet · 2014 · PMID 24705250 · validated civic_curation pubmed

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.

· Nat Genet · 2014 · PMID 24705251 · validated civic_curation pubmed

Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.

· Nat Genet · 2012 · PMID 22286216 · validated civic_curation pubmed

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.

· Proc Natl Acad Sci U S A · 2013 · PMID 23530248 · validated civic_curation pubmed

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.

· Nat Genet · 2014 · PMID 24705254 · validated civic_curation pubmed

Polymorphisms of CDKN1A gene and risk of retinoblastoma.

· Carcinogenesis · 2013 · PMID 24045412 · validated civic_curation pubmed

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.

· Lancet Oncol · 2019 · PMID 31151904 · validated civic_curation pubmed

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

· Oncotarget · 2012 · PMID 23104868 · validated civic_curation pubmed

Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.

· Nat Genet · 2014 · PMID 24705252 · validated civic_curation pubmed

A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).

· Neuro Oncol · 2014 · PMID 24311637 · validated civic_curation pubmed

Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.

· Acta Neuropathol · 2015 · PMID 26399631 · validated civic_curation pubmed

C11orf95-RELA fusions drive oncogenic NF-κB signalling in ependymoma.

· Nature · 2014 · PMID 24553141 · validated civic_curation pubmed

A multi-institutional retrospective pooled outcome analysis of molecularly annotated pediatric supratentorial ZFTA-fused ependymoma.

· Neurooncol Adv · 2023 · PMID 37287693 · validated civic_curation pubmed

Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial.

· Neuro Oncol · 2019 · PMID 30976811 · validated civic_curation pubmed